Q-omics provides the consensus-scored CICP22 profile across patient tissues and cancer cell-line models. CICP22 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CICP22 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, CICP22 RNA expression shows 15,660 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where CICP22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP22 survival associations across molecular data types. CICP22 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP22 RNA expression–survival associations across cancer types. High CICP22 expression shows unfavorable associations in UVM, READ, MESO and CESC, but favorable associations in PAAD and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CICP22 RNA expression.
This table summarizes CICP22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CICP22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP22 shows lower tumor expression in THCA and higher tumor expression in KICH, LUAD, BRCA, LUSC and COAD. The KICH box plot shows higher CICP22 RNA expression in tumor versus normal tissue (log2 FC = +0.378, t-test p < 0.001).
This table shows molecular features associated with CICP22 in patient tissues and cancer cell lines. In patient samples, CICP22 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
